Journal of Veterinary Science

  • 제22권6호
  • /
  • Pages.79.1-79.14
  • /
  • 2021
  • /
  • 1229-845X(pISSN)
  • /
  • 1976-555X(eISSN)
대한수의학회 (The Korean Society of Veterinary Science)
권호 표지
DOI QR코드

DOI QR Code

Investigation of serum survivin in dogs suffering from cancer: a multicenter study

  • Estaller, Annkathrin (Small Animal Clinic, Institute of Veterinary Medicine, Georg-August University of Gottingen) ;
  • Kessler, Martin (Small Animal Clinic Hofheim) ;
  • Wehrend, Axel (Clinic of Obstetrics, Gynaecology and Andrology of Large and Small Animals of the Justus-LiebigUniversity Giessen) ;
  • Gessler, Frank (Miprolab GmbH) ;
  • Hirschberger, Johannes (Clinic of Small Animal Medicine, Ludwig Maximilian University of Munich) ;
  • Neumann, Stephan (Small Animal Clinic, Institute of Veterinary Medicine, Georg-August University of Gottingen)
  • 투고 : 2021.05.12
  • 심사 : 2021.08.24
  • 발행 : 2021.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: In contrast to human medicine, only a small number of serum tumor markers are established in veterinary medicine even though they are a non-invasive diagnostic tool. Objectives: This study examined whether survivin could be suitable as a potential canine serum tumor marker. Methods: This study measured the serum survivin concentrations of dogs with mammary tumors (n = 33), squamous cell carcinoma (n = 9), soft-tissue sarcoma (n = 18) and multicentric lymphoma (n = 22), using a commercially available, competitive immunoassay kit (BlueGene). The serum survivin concentrations were compared with those of a healthy control group (n = 20) and a control group of dogs with non-neoplastic diseases (n = 17). Results: Dogs with malignant tumors had serum survivin concentrations between 15 and 5,906 pg/mL (median, 72 pg/mL), those in the healthy group ranged from 7 to 99 pg/mL (median, 21 pg/mL) and those in the group of dogs suffering from non-neoplastic diseases from 15 to 93 pg/mL (median, 42 pg/mL). The differences in the survivin concentrations between the healthy dogs and dogs with malignant tumors and between the dogs with non-neoplastic diseases and those with malignant tumors were significant (p < 0.001 and p = 0.006, respectively). Conclusions: The serum survivin concentrations in dogs with malignant tumors, with some exceptions, are higher than in dogs with benign tumors and dogs that do not suffer from a malignancy. Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs.

키워드

참고문헌

  1. Veiga GLD, Silva RDMD, Pereira EC, Azzalis LA, Alves BDCA, Gehrke FS, et al. The role of survivin as a biomarker and potential prognostic factor for breast cancer. Rev Assoc Med Bras (1992). 2019;65(6):893-901. https://doi.org/10.1590/1806-9282.65.6.893
  2. Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem. 2007;22(1):57-60. https://doi.org/10.1007/BF02912882
  3. Wang YR, Yan JX, Wang LN. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer. J Cancer Res Ther. 2014;10 Suppl:307-309. https://doi.org/10.4103/0973-1482.151538
  4. Soltani K. Alpha-fetoprotein: a review. J Invest Dermatol. 1979;72(5):211-213. https://doi.org/10.1111/1523-1747.ep12530749
  5. Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol. 2005;247:35-88. https://doi.org/10.1016/s0074-7696(05)47002-3
  6. Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci. 2008;17(9):1624-1629. https://doi.org/10.1110/ps.036145.108
  7. Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79(11):1327-1333.
  8. Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci. 2019;132(7):jcs223826. https://doi.org/10.1242/jcs.223826
  9. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152(1):43-49.
  10. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5):1087-1098. https://doi.org/10.1158/1535-7163.MCT-05-0375
  11. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917-921. https://doi.org/10.1038/nm0897-917
  12. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet. 1999;23(4):387-388.
  13. Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001;76(3):169-173. https://doi.org/10.1016/s0165-2478(01)00186-9
  14. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99(7):4349-4354. https://doi.org/10.1073/pnas.072586399
  15. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006;66(20):10100-10111. https://doi.org/10.1158/0008-5472.CAN-06-1684
  16. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826. https://doi.org/10.1056/NEJMoa041588
  17. Kavya N, Rao S, Sathyanarayana ML, Narayanaswamy HD, Byregowda SM, Ranganath L, et al. Survivin expression in canine spontaneous cutaneous and subcutaneous tumors and its prognostic importance. Vet World. 2017;10(10):1286-1291. https://doi.org/10.14202/vetworld.2017.1286-1291
  18. Shoeneman JK, Ehrhart EJ 3rd, Eickhoff JC, Charles JB, Powers BE, Thamm DH. Expression and function of survivin in canine osteosarcoma. Cancer Res. 2012;72(1):249-259. https://doi.org/10.1158/0008-5472.CAN-11-2315
  19. Tango Y, Kano R, Maruyama H, Asano K, Tanaka S, Hasegawa A, et al. Detection of autoantibodies against survivin in sera from cancer dogs. J Vet Med Sci. 2010;72(7):917-920. https://doi.org/10.1292/jvms.09-0476
  20. Jena SC, Shrivastava S, Saxena S, Kumar N, Maiti SK, Mishra BP, et al. Surface plasmon resonance immunosensor for label-free detection of BIRC5 biomarker in spontaneously occurring canine mammary tumours. Sci Rep. 2019;9(1):13485. https://doi.org/10.1038/s41598-019-49998-x
  21. Sharma S. Tumor markers in clinical practice: general principles and guidelines. Indian J Med Paediatr Oncol. 2009;30(1):1-8. https://doi.org/10.4103/0971-5851.56328
  22. Kaszak I, Ruszczak A, Kanafa S, Kacprzak K, Krol M, Jurka P. Current biomarkers of canine mammary tumors. Acta Vet Scand. 2018;60(1):66. https://doi.org/10.1186/s13028-018-0417-1
  23. Yamazaki H, Takagi S, Hoshino Y, Hosoya K, Okumura M. Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines. PLoS One. 2013;8(11):e79810. https://doi.org/10.1371/journal.pone.0079810
  24. Mobasheri A, Cassidy JP. Biomarkers in veterinary medicine: Towards targeted, individualised therapies for companion animals. Vet J. 2010;185(1):1-3. https://doi.org/10.1016/j.tvjl.2010.04.003
  25. Henry CJ. Biomarkers in veterinary cancer screening: Applications, limitations and expectations. Vet J. 2010;185(1):10-14. https://doi.org/10.1016/j.tvjl.2010.04.005
  26. Harting T, Stubbendorff M, Willenbrock S, Wagner S, Schadzek P, Ngezahayo A, et al. The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro. Int J Oncol. 2016;49(6):2341-2350. https://doi.org/10.3892/ijo.2016.3720
  27. Chen G. The relationship between the expression of TAM, survivin and the degree of necrosis of the tumor after cisplatin treatment in osteosarcoma. Eur Rev Med Pharmacol Sci. 2017;21(3):490-497.
  28. Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. 2014;14(1):176. https://doi.org/10.1186/1471-2407-14-176
  29. Lodi G, Franchini R, Bez C, Sardella A, Moneghini L, Pellegrini C, et al. Detection of survivin mRNA in healthy oral mucosa, oral leucoplakia and oral cancer. Oral Dis. 2010;16(1):61-67. https://doi.org/10.1111/j.1601-0825.2009.01614.x
  30. Lechler P, Wu X, Bernhardt W, Campean V, Gastiger S, Hackenbeck T, et al. The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney. Am J Pathol. 2007;171(5):1483-1498. https://doi.org/10.2353/ajpath.2007.070132
  31. Gravina G, Wasen C, Garcia-Bonete MJ, Turkkila M, Erlandsson MC, Toyra Silfversward S, et al. Survivin in autoimmune diseases. Autoimmun Rev. 2017;16(8):845-855. https://doi.org/10.1016/j.autrev.2017.05.016
  32. Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, et al. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology. 2007;54(79):2040-2044.
  33. Yamada T, Fujita M, Kitao S, Ashida Y, Nishizono K, Tsuchiya R, et al. Serum alpha-fetoprotein values in dogs with various hepatic diseases. J Vet Med Sci. 1999;61(6):657-659. https://doi.org/10.1292/jvms.61.657
  34. Lechowski R, Jagielski D, Hoffmann-Jagielska M, Zmudzka M, Winnicka A. Alpha-fetoprotein in canine multicentric lymphoma. Vet Res Commun. 2002;26(4):285-296. https://doi.org/10.1023/A:1016086508286
  35. Goldschmidt M, Pena L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol. 2011;48(1):117-131. https://doi.org/10.1177/0300985810393258
  36. Gunaldi M, Isiksacan N, Kocoglu H, Okuturlar Y, Gunaldi O, Topcu TO, et al. The value of serum survivin level in early diagnosis of cancer. J Cancer Res Ther. 2018;14(3):570-573. https://doi.org/10.4103/0973-1482.171369
  37. Hoo ZH, Candlish J, Teare D. What is an ROC curve? Emerg Med J. 2017;34(6):357-359. https://doi.org/10.1136/emermed-2017-206735
  38. Senhorello ILS, Terra EM, Sueiro FAR, Firmo BF, Anai LA, Goloni C, et al. Clinical value of carcinoembryonic antigen in mammary neoplasms of bitches. Vet Comp Oncol. 2020;18(3):315-323. https://doi.org/10.1111/vco.12552
  39. Hu J, Wang N, Yang Y, Ma L, Han R, Zhang W, et al. Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma. BMC Gastroenterol. 2018;18(1):186. https://doi.org/10.1186/s12876-018-0908-6
  40. Carvalho MI, Pires I, Prada J, Queiroga FL. A role for T-lymphocytes in human breast cancer and in canine mammary tumors. BioMed Res Int. 2014;2014:130894. https://doi.org/10.1155/2014/130894